Mark Joseph Vignola
Net Worth
Last updated:
What is Mark Joseph Vignola net worth?
The estimated net worth of Dr. Mark Joseph Vignola is at least $1,896,601 as of 10 Sep 2024. He owns shares worth $580,151 as insider, has earned $110,000 from insider trading and has received compensation worth at least $1,206,450 in Terns Pharmaceuticals, Inc..
What is the salary of Mark Joseph Vignola?
Dr. Mark Joseph Vignola salary is $402,150 per year as Chief Financial Officer & Treasurer in Terns Pharmaceuticals, Inc..
How old is Mark Joseph Vignola?
Dr. Mark Joseph Vignola is 47 years old, born in 1978.
What stocks does Mark Joseph Vignola currently own?
As insider, Dr. Mark Joseph Vignola owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) | Chief Financial Officer & Treasurer | 91,940 | $6.31 | $580,151 |
What does Terns Pharmaceuticals, Inc. do?
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Mark Joseph Vignola insider trading
Terns Pharmaceuticals, Inc.
Dr. Mark Joseph Vignola has made only one insider trade between 2022-2024, according to the Form 4 filled with the SEC.
As of 10 Sep 2024 he still owns at least 91,940 units of TERN stock.
Terns Pharmaceuticals key executives
Terns Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Erin Quirk M.D. (54) Head of R&D, Pres & Chief Medical Officer
- Dr. Mark Joseph Vignola (47) Chief Financial Officer & Treasurer
- Mr. Senthil Vel Sundaram (47) Chief Executive Officer & Director